戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  camptothecin sensitivity of yeast and human DNA topoisomerase I.
2 -kDa N-terminal fragment of Escherichia coli DNA topoisomerase I.
3 t of the known structures of yeast and human DNA topoisomerase I.
4 nd unwinds DNA in the presence of eukaryotic DNA topoisomerase I.
5  shown previously to act as poisons of human DNA topoisomerase I.
6 nhibit RNA topoisomerase activity of E. coli DNA topoisomerase I.
7 ding of the modified DNA substrates by human DNA topoisomerase I.
8 mplate and DNA synthesis absolutely required DNA topoisomerase I.
9 upercoiled in Escherichia coli cells lacking DNA topoisomerase I.
10  chain and amino acids of the active site of DNA topoisomerase I.
11  found to have 100% sequence homologies with DNA topoisomerase I.
12  does not result from elevated expression of DNA topoisomerase I.
13 on of DNA damage induced by camptothecin and DNA topoisomerase I.
14 aining a deletion of topA (the gene encoding DNA topoisomerase I) a compensatory mutation is found in
15 substitution mutagenesis of Escherichia coli DNA topoisomerase I, a member of the type IA subfamily o
16 eplisomes with camptothecin (CPT)-stabilized DNA-Topoisomerase I adducts activates an ATR-dependent p
17 Therapy for ERMS included alkylating agents, DNA topoisomerase I and DNA topoisomerase II inhibitors,
18 ation, YCS4 function is required to localize DNA topoisomerase I and II to chromosomes.
19 vity to their Escherichia coli counterparts, DNA topoisomerase I and III (ecTopo I, ecTopo III).
20                        These genes, encoding DNA topoisomerase I and IIIalpha (bcTopo I, bcTopo IIIal
21 thin the other component are factors, namely DNA topoisomerase I and PC4, previously shown to serve a
22  the nuclear mitotic apparatus protein NuMA, DNA topoisomerases I and II, and the RNA polymerase I up
23  results, E. coli cells lacking both type IA DNA topoisomerases I and III are found to be nonviable,
24 urther confirmed to be DNA polymerase alpha, DNA topoisomerase I, and PCNA by immunoprecipitation exp
25                            Autoreactive anti-DNA topoisomerase I (anti-Topo I) Abs are commonly detec
26  RNP, anti-SSA/Ro, anti-SSB/La, anti-Scl-70 (DNA topoisomerase I), anticentromere, and anti-Jo-1 anti
27 the active site tyrosine of Escherichia coli DNA topoisomerase I are conserved among the type IA topo
28 11, Asp-113, and Glu-115 of Escherichia coli DNA topoisomerase I are located near the active site Tyr
29                                  The role of DNA topoisomerase I as a biochemical mediator of radiose
30                         The results identify DNA topoisomerase I as a novel self-antigen in transplan
31  DNA from the 5' side of a nick generated by DNA topoisomerase I at a ribonucleoside monophosphate re
32 hput assay to screen for inhibitors of human DNA topoisomerase I based on the scintillation proximity
33 termined for stabilization of the unmodified DNA-topoisomerase I binary complex.
34                                     Putative DNA topoisomerase I binding sites were clustered around
35 -b]pyran-5,6-dione (beta-lapachone) inhibits DNA topoisomerase I by a mechanism distinct from that of
36     The antitumor agent camptothecin targets DNA topoisomerase I by reversibly stabilizing a covalent
37 l result in severely compromised enzymes and DNA topoisomerase I-camptothecin dependent lethality.
38                                   Eukaryotic DNA topoisomerase I catalyzes the relaxation of supercoi
39 NA-protein cross-links, which include stable DNA-topoisomerase I cleavable complexes.
40  a new class of anticancer drugs that target DNA topoisomerase I; current efforts are directed toward
41                             Escherichia coli DNA topoisomerase I (encoded by the topA gene) is import
42                                          The DNA topoisomerase I enzyme of Mycobacterium tuberculosis
43    The nucleotide sequence of the Drosophila DNA topoisomerase I gene (top1) has been determined.
44 xtraction, regions of the DNA polymerase and DNA topoisomerase I genes were amplified by PCR, sequenc
45 logical probe, we find that Escherichia coli DNA topoisomerase I has low RNA topoisomerase activity a
46      Commonly used antitumor agents, such as DNA topoisomerase I/II poisons, kill cancer cells by cre
47 e response represents a new role for E. coli DNA topoisomerase I in addition to prevention of excessi
48 icting results regarding the essentiality of DNA topoisomerase I in cells grown in media of low osmol
49 nd evaluated for their ability to trap human DNA topoisomerase I in cleavable complexes.
50 ults thus implicate an indispensable role of DNA topoisomerase I in E. coli cells grown in media of a
51  the rDNA and clarifies a structural role of DNA topoisomerase I in the epigenetic regulation of rDNA
52            The proposed mechanism of type IA DNA topoisomerase I includes conformational changes by t
53  Mutations in two conserved regions of yeast DNA topoisomerase I induced a similar mechanism of cell
54 lkynyl side chains display excellent E. coli DNA topoisomerase I inhibition properties with IC50 valu
55  been synthesized and their Escherichia coli DNA topoisomerase I inhibition, binding to B-DNA duplex,
56 The anticancer agent camptothecin (CPT) is a DNA topoisomerase I inhibitor that causes fork collapse
57 RISPR-Cas9 screens in cells treated with the DNA topoisomerase I inhibitor topotecan.
58 sphorylated within 1 h after addition of the DNA topoisomerase I inhibitor, camptothecin, and that la
59 ramatically sensitizes glioblastoma cells to DNA topoisomerase I inhibitor-mediated apoptosis.
60  mutant after treatment with camptothecin, a DNA topoisomerase I inhibitor.
61           Compounds 10, 12, and 19 displayed DNA topoisomerase I inhibitory activity in vitro and com
62 one (2k), which exhibited the characteristic DNA topoisomerase-I inhibitory mechanism of action with
63 matography and overlay blotting that E. coli DNA topoisomerase I interacts directly with the RNA poly
64 titumor agent that kills cells by converting DNA topoisomerase I into a DNA-damaging poison.
65                                              DNA topoisomerase I is an essential nuclear enzyme invol
66 raction between camptothecin derivatives and DNA topoisomerase I is essential in the induction of rad
67              Camptothecin (CPT) that targets DNA topoisomerase I is one of the most promising broad-s
68  the NUP98 FXFG repeats fused to the body of DNA topoisomerase I is produced.
69                                              DNA topoisomerase I is required for the relaxation of ne
70                                    Bacterial DNA topoisomerase I is responsible for preventing the hy
71                                              DNA topoisomerase I is the cytotoxic target for chemothe
72 stidine residue, His-365 in Escherichia coli DNA topoisomerase I, is located at the active site of ty
73                                   Eukaryotic DNA topoisomerase I manipulates the higher order structu
74 lts suggest distinct mechanisms of poisoning DNA topoisomerase I may be explored in the development o
75  mechanisms underlying cellular responses to DNA topoisomerase I-mediated DNA damage are conserved be
76 itional mutants with enhanced sensitivity to DNA topoisomerase I-mediated DNA damage.
77 t study, we investigated the role of Ku86 in DNA topoisomerase I-mediated radiosensitization induced
78  with enhanced sensitivity to self-poisoning DNA topoisomerase I mutant (Top1T722Ap), which mimics th
79 ture-sensitive growth in the presence of the DNA topoisomerase I mutant, Top1T722Ap, were selected.
80 to the cytotoxic activity of Cpt or specific DNA topoisomerase I mutants, we initiated a genetic scre
81              Although they are known to trap DNA topoisomerase I on DNA, form cleavable complexes, an
82  patients with SSc who are positive for anti-DNA topoisomerase I or anticentromere autoantibodies.
83 SSc patients who had either circulating anti-DNA topoisomerase I (P=7.58x10(-17)/4.84x10(-16)) or ant
84 gainst >4000 potential autoantigens revealed DNA topoisomerase I peptide 205-219 (TI-I(205-219)) as t
85 hecin interferes with the catalytic cycle of DNA topoisomerase I rendering it a cellular poison.
86                             Escherichia coli DNA topoisomerase I requires Mg(II) as a cofactor for th
87 inus of this alpha helix in Escherichia coli DNA topoisomerase I showed that flexibility around this
88 gs1 top1 double mutant lacking both Sgs1 and DNA topoisomerase I showed that the slow growth phenotyp
89 a protein homologous to the Escherichia coli DNA topoisomerase I subfamily of enzymes has been identi
90 her in vivo evaluation of the combination of DNA topoisomerase I-targeted drugs and mTOR kinase inhib
91                 In this study, we found that DNA topoisomerase I-targeted drugs and mTOR kinase inhib
92 rity, results from the synthesis of a mutant DNA topoisomerase I that is itself temperature-sensitive
93         The bacteriophage T4-encoded type II DNA topoisomerase is the major target for the antitumour
94      We have used the properties of Vaccinia DNA topoisomerase I to develop a ligase-free technology
95 ts, such as the 3'-phosphotyrosyl linkage of DNA topoisomerase I to DNA.
96                               The ability of DNA topoisomerase I to mediate the formation of structur
97                                              DNA topoisomerase I (top I) is the target of the antitum
98               The effects of such lesions on DNA topoisomerase I (top1) activity were examined in oli
99 n (CPT) and its derivatives target mammalian DNA topoisomerase I (top1) and are among the most effect
100       These deletion events are dependent on DNA topoisomerase I (Top1) and are initiated by Top1 inc
101               The catalytic intermediates of DNA topoisomerase I (top1) are cleavage complexes that c
102 s such as DNA replication and transcription, DNA topoisomerase I (Top1) catalyzes the relaxation of D
103                               In eukaryotes, DNA topoisomerase I (Top1) catalyzes the relaxation of s
104      When a replication fork collides with a DNA topoisomerase I (Top1) cleavage complex, the covalen
105                                              DNA topoisomerase I (TOP1) has an important role in main
106                            The inhibition of DNA topoisomerase I (Top1) has proven to be a successful
107 il (FU), is most closely correlated with the DNA topoisomerase I (Top1) inhibitor camptothecin in the
108 modified DNA lesions have been shown to trap DNA topoisomerase I (TOP1) into covalent cleavage comple
109 s containing wild-type and mutant alleles of DNA topoisomerase I (TOP1) into the haploid yeast gene-d
110                                   Eukaryotic DNA topoisomerase I (Top1) is a monomeric protein clamp
111                                              DNA topoisomerase I (top1) is a ubiquitous enzyme that f
112                                              DNA topoisomerase I (Top1) is the target of camptothecin
113                                              DNA topoisomerase I (top1) is the target of potent antic
114                                              DNA topoisomerase I (TOP1) mediates the induction of rad
115                                Human nuclear DNA topoisomerase I (top1) plays a crucial role in DNA r
116 t (H(432)R) enhanced cell sensitivity to the DNA topoisomerase I (Top1) poison camptothecin.
117 reated with camptothecin (CPT), a eukaryotic DNA topoisomerase I (TOP1) poison which induces TOP1-med
118 e show rapid recruitment, within minutes, of DNA topoisomerase I (TOP1) to a large cohort of AR-regul
119  uracil mismatches, nicks, and gaps can trap DNA topoisomerase I (top1) when these lesions are introd
120                              The activity of DNA topoisomerase I (Top1), an enzyme that regulates DNA
121  20q11 occurs within the gene encoding human DNA topoisomerase I (TOP1).
122 t are synthetically lethal with mutations in DNA topoisomerase I (top1).
123                                   Eukaryotic DNA topoisomerase I (Top1p) catalyzes changes in DNA top
124                                              DNA topoisomerase I (Top1p) catalyzes changes in DNA top
125                                   Eukaryotic DNA topoisomerase I (Top1p) catalyzes changes in DNA top
126                                              DNA topoisomerase I (Top1p) catalyzes the relaxation of
127                                   Eukaryotic DNA topoisomerase I (Top1p) catalyzes the relaxation of
128                                              DNA topoisomerase I (Top1p) catalyzes topological change
129                                   Eukaryotic DNA topoisomerase I (Top1p) has important functions in D
130 show that mutations in the gene encoding for DNA topoisomerase I (topA) give rise to mutator phenotyp
131 cherichia coli (Ec) topA gene, which encodes DNA topoisomerase I (TopI).
132 tokines in regulating the production of anti-DNA topoisomerase I (topo I) Ab, a major autoantibody in
133 xyl-terminal amino acids of Escherichia coli DNA topoisomerase I (Topo I) and III (Topo III) play in
134 ssesses two type I topoisomerase activities, DNA topoisomerase I (Topo I) and III (Topo III).
135                            Autoantibodies to DNA topoisomerase I (topo I) are associated with diffuse
136                    Autoantibody responses to DNA topoisomerase I (Topo I) are highly specific to pati
137                                              DNA topoisomerase I (topo I) from Drosophila melanogaste
138                                              DNA topoisomerase I (topo I) is an essential enzyme invo
139                                        Human DNA topoisomerase I (topo I) is an essential mammalian e
140  hydrophilic N-terminal domain of eukaryotic DNA topoisomerase I (topo I) is dispensable for catalyti
141                                              DNA topoisomerase I (topo I) is involved in the regulati
142                                              DNA topoisomerase I (topo I) is involved in the regulati
143                                              DNA topoisomerase I (topo I) is known to participate in
144 f the deduced amino acid sequence with other DNA topoisomerase I (topo I) protein sequences shows a s
145             The mechanism of coactivation by DNA topoisomerase I (topo I) was examined in a highly de
146 luding DNA polymerase alpha (DNA pol alpha), DNA topoisomerase I (topo I), and proliferating-cell nuc
147 responses to various autoantigens, including DNA topoisomerase I (Topo I), have been implicated.
148 anticancer drugs slow the religation step of DNA topoisomerase I (topo I).
149 ent that inhibits the activity of the enzyme DNA topoisomerase-I (topo-I).
150 inding DNA ligands that uses closed circular DNA, topoisomerase I (Topo I), and two-dimensional agaro
151 tigens and also revealed increased levels of DNA topoisomerase I transcripts in SSc fibroblasts compa
152        The DNA cleavage-ligation reaction of DNA topoisomerase I was investigated employing synthetic
153    The viability of the topA mutants lacking DNA topoisomerase I was thought to depend on the presenc
154 merase and the C-terminal domains of E. coli DNA topoisomerase I, which are homologous to the zinc ri
155  AA-etherA inhibition of DNA replication are DNA topoisomerase I, which is inhibited by AA-etherA in
156        Two distinct tissue-specific forms of DNA topoisomerase I with M(r) of 165 and 110 kDa have be
157 n yeast (delta)top1 cells lacking endogenous DNA topoisomerase I yielded an activity in cell extracts

 
Page Top